Omrix Biopharmaceuticals

Company Overview

Snapshot

Founded in June 1995, Omrix Biopharmaceuticals operated with 201–500 employees. The company raised $4.84 million across two funding rounds from two investors. A significant milestone was its acquisition by Johnson & Johnson in November 2008.

Business overview

Omrix Biopharmaceuticals specializes in the development and manufacture of products derived from human plasma, leveraging patented technology for global distribution. The company's product portfolio includes biosurgical sealants for hemostasis during surgery and passive immunotherapy products for immune-deficient patients. Omrix operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices industry with its medical treatment and therapeutics, and biologicals products.

Company Intelligence Q&A

What was the most significant corporate event for Omrix Biopharmaceuticals?

Omrix Biopharmaceuticals was acquired by Johnson & Johnson in November 2008. This acquisition marked the culmination of an eight-year partnership between the two companies.

When did Omrix Biopharmaceuticals go public?

Omrix Biopharmaceuticals completed an Initial Public Offering (IPO) on NASDAQ in January 2005.

When was Omrix Biopharmaceuticals delisted from NASDAQ?

Omrix Biopharmaceuticals was delisted from NASDAQ in January 2009, following its acquisition by Johnson & Johnson.

Which investors participated in Omrix Biopharmaceuticals' funding round in March 2005?

In March 2005, Omrix Biopharmaceuticals received funding from investors including Catalyst.

What was the acquisition amount for Omrix Biopharmaceuticals by Johnson & Johnson?

Johnson & Johnson acquired Omrix Biopharmaceuticals for $465 million in November 2008.